Somatic Activation of KIT in Distinct Subtypes of Melanoma

20061,584 citationsJournal Articlebronze Open Access

Authors

John A. Curtin · University of California, San Francisco

Klaus J. Busam · UCSF Helen Diller Family Comprehensive Cancer Center

Daniel Pinkel · UCSF Helen Diller Family Comprehensive Cancer Center

Boris C. Bastian · UCSF Helen Diller Family Comprehensive Cancer Center

Abstract

KIT is an important oncogene in melanoma. Because the majority of the KIT mutations we found in melanoma also occur in imatinib-responsive cancers of other types, imatinib may offer an immediate therapeutic benefit for a significant proportion of the global melanoma burden.

Topics & Keywords

Cutaneous Melanoma Detection and Management Gastrointestinal Tumor Research and Treatment Sarcoma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 24, Issue 26, pp. 4340-4346

DOI: 10.1200/jco.2006.06.2984

Field-Weighted Citation Impact: 28.49